StockNews.com Begins Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)

Research analysts at StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Price Performance

Shares of CPIX stock opened at $1.42 on Thursday. Cumberland Pharmaceuticals has a twelve month low of $1.42 and a twelve month high of $2.36. The stock has a market capitalization of $20.14 million, a price-to-earnings ratio of -3.23 and a beta of 0.16. The stock has a fifty day simple moving average of $1.82 and a two-hundred day simple moving average of $1.87. The company has a current ratio of 1.28, a quick ratio of 1.11 and a debt-to-equity ratio of 0.44.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 6.84% and a negative net margin of 15.87%. The firm had revenue of $9.35 million during the quarter.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

An institutional investor recently bought a new position in Cumberland Pharmaceuticals stock. Bank of New York Mellon Corp acquired a new position in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 75,268 shares of the specialty pharmaceutical company’s stock, valued at approximately $142,000. Bank of New York Mellon Corp owned about 0.52% of Cumberland Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.